Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: Results from a pilot trial

Cancer Chemotherapy and Pharmacology

Volumn 57, Issue 5, 2006, Pages 554-558

  Bartsch, Rupert ^a   Wenzel, Catharina ^a   Pluschnig, Ursula ^a   Hussian, Dagmar ^a   Sevelda, Ursula ^a   Locker, Gottfried J ^a   Mader, Robert ^a   Zielinski, Christoph C ^a   Steger, Guenther G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Advanced breast cancer; Immunotherapy; Oral vinorelbine; Palliative chemotherapy; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NAVELBINE; NAVELBINE ORAL; TRASTUZUMAB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE CALCULATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; NAUSEA; NEUTROPENIA; POLYNEUROPATHY; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; PILOT PROJECTS; RECEPTOR, ERBB-2; SKIN NEOPLASMS; SURVIVAL RATE; VINBLASTINE;

EID: 32544459112     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0092-6     Document Type: Article

References (27)

1. Ligibel JA, Winer EP (2002) Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Oncol 29:38-43
2. Thomssen C (2001) Trials of new combinations of Herceptin in metastatic breast cancer. Anticancer Drugs 12(Suppl. 4):S19-S25
3. Vogel CL, Franco SX (2003) Clinical experience with trastuzumab (herceptin). Breast J 9:452-462
4. Burstein HJ, Harris LN, Marcom PK, et al (2003) Trastuzumab and vinorelbine as first-line therapy for Her2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21:2889-2895
5. Winer EP, Burstein HJ (2001) New combinations with herceptin in metastatic breast cancer. Oncology 61(Suppl. 2):50-57
6. Jahanzeb M, Mortimer JE, Yunus F, et al (2002) Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with Her2(+) metastatic breast cancer. Oncologist 7:410-417
7. Montemurro F, Valabrega G, Aglietta M (2004) Trastuzumab-based combination therapy for breast-cancer. Expert Opin Pharmacother 5:81-96
8. Jahanzeb M (2003) Trastuzumab-based combinations in metastatic breast cancer: how to make a choice. Clin Breast Cancer 1:28-38
9. Suzuki Y, Tokuda Y, Saito Y, et al (2003) Combination of trastuzumab and vinorelbine in metastatic breast cancer. Jpn J Clin Oncol 33:514-517
10. Winer EP, Burstein HJ (2001) New combinations with herceptin in metastatic breast cancer. Oncology 61(Suppl. 2):50-57
11. Burstein HJ, Kuter I, Campos SM, et al (2004) Clinical activity of trastuzumab and vinorelbine in women with Her2-overexpressing breast cancer. J Clin Oncol 15:2722-2730
12. Leveque D, Jehl F (1996) Clinical pharmacokinetics of vinorelbine. Clin Pharmacokinet 32:323
13. Smith GA (1995) Current status of vinorelbine for breast cancer. Oncology (Huntingt) 9:767-773
14. Rossi A, Gridelli C, Gebbia V, et al (2003) Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer. Anticancer Res 23:1657-1664
15. Depierre A, Freyer G, Jassem J, et al (2001) Oral vinorelbine: feasibility and safety profile. Ann Oncol 12:1677-1681
16. Variol P, Nguyen L, Tranchand B, et al (2002) A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine. Eur J Clin Pharmacol 58:467-476
17. Burstein HJ, Kuter I Campos SM, et al (2004) Clinical activity of trastuzumab and vinorelbine in women with Her2-overexpressing metastatic breast cancer. J Clin Oncol 19:2722-2730
18. Bonneterre J, Chevalier B, Focan C, et al (2001) Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC). Ann Oncol 12:1683-1691
19. Carlson RW (1998) Quality of life issues in the treatment of metastatic breast cancer. Oncology (Huntingt) 12:27-31
20. Leyland-Jones B, Gelmon K, Ayoub JP, et al (2003) Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 21:3965-3971
21. Kaplan EL, Meier P (1958) Non parametric estimation for incomplete observations. J Am Stat Assoc 53:457-481
22. ÓShaughnessy J, Miles D, Vukelja S (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812-2823
23. Freyer G, Delozier T, Lichinister M, et al (2003) Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 21:35-40
24. Trillet-Lenoir V, Sommer H, Delozier T, et al (2004) Oral vinorelbine in metastatic breast cancer: long term results of 2 phase II studies. Eur J Cancer 2(Suppl.):Abstract 279
25. Slamon DJ, Clark GM, Wong SG, et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235:177-182
26. Boss JS, Fletcher JA, Linette GP (2003) The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8:307-325
27. Paik S, Hazan R, Fisher ER, et al (1990) Pathologic finding from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein expression in primary breast cancer. J Clin Oncol 8:103-112